The Wee1 Like Protein Kinase pipeline drugs market research report outlays comprehensive information on the Wee1 Like Protein Kinase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Wee1 Like Protein Kinase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Oncology which include the indications Solid Tumor, and Ovarian Cancer. It also reviews key players involved in Wee1 Like Protein Kinase targeted therapeutics development with respective active and dormant or discontinued products.
The Wee1 Like Protein Kinase pipeline targets constitutes close to 13 molecules. Out of which, approximately 13 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 4, 4, 2, and 3 respectively.
Wee1 Like Protein Kinase overview
Wee1-like protein kinase (WEE1) is a protein that catalyzes the inhibitory tyrosine phosphorylation of CDC2/cyclin B kinase and appears to coordinate the transition between DNA replication and mitosis by protecting the nucleus from cytoplasmically activated CDC2 kinase.
For a complete picture of Wee1 Like Protein Kinase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.